The Top 5 Biosimilars Articles for the Week of July 22

July 26, 2019

The Center for Biosimilars® recaps the top stories for the week of July 22, 2019.

Transcript

Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of July 22, 2019.

Number 5: Sandoz announced that it has enrolled its first patient in a study of a proposed biosimilar, GP2411.

Number 4: The European Medicines Agency will review Samsung Bioepis’ proposed biosimilar, SB8.

Number 3: A new paper argues that regulators should affirm the interchangeability of approved biosimilars.

Number 2: The FDA approved its fourth adalimumab biosimilar on Tuesday.

Number 1: Also on Tuesday, the FDA approved its second rituximab biosimilar.

Finally, last week, our e-newsletter asked whether you think that advocacy groups will play a role in US biosimilar uptake.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.